Drug Topics December 2021

On September 28, the FDA granted approval to oral atogepant (Qulipta) for the prevention of migraine.

As we head into 2022, the pharmaceutical industry still faces uncertainty stemming from supply chain challenges.

Overwhelmed pharmacists are no longer scared of speaking up to managers.

MyRx PRO is a comprehensive pharmacy management platform that streamlines workflows, increases optimization, and helps pharmacies maximize their bottom line through artificial intelligence–powered pricing intelligence.

From medication to legislation, multiple developments have advanced the pharmacy profession this year.

Most pharmacists are moderately to not-at-all comfortable answering patient questions about cannabis. That needs to change.

Pharmacists discuss the best methods for postoperative opioid prescription management.

Each autumn, Drug Topics® surveys its readers from across the country to take the pulse of the pharmacy profession before heading into the new year. This year, 1123 respondents were more eager than perhaps ever before to share their feelings on important workplace issues.

Highlights included updates on COVID-19 vaccine tolerance in individuals with rheumatic diseases, the latest data on medical cannabis use in fibromyalgia, and more.

The COVID-19 pandemic and social media have resulted in extreme levels of misinformation.

Questions continue to swirl around eligibility for these shots.

Influenza is expected to make a comeback this year, and no one knows how severe it may be.

Mobile apps and fitness trackers predate the COVID-19 pandemic but are being utilized more ever before.